Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India

In a statement, Pfizer said it had decided to withdraw the application after a meeting with the Drug Regulatory Authority of India on 3 Feb, in which the regulator stated that there may be need for 'additional information'

Press Trust of India February 05, 2021 15:54:45 IST
Pfizer withdraws application for emergency use authorisation of its COVID-19 vaccine in India

Representational image. AP

New Delhi: Pharma major Pfizer on Friday said it has decided to withdraw its application for Emergency Use Authorisation (EUA) of its COVID-19 vaccine in India.

Pfizer was the first pharmaceutical firm to seek an emergency use authorisation from the Drugs Controller General of India (DCGI) for its COVID-19 vaccine in the country, after it secured such clearance in the UK and Bahrain.

"In pursuance of the Emergency Use Authorisation of its COVID-19 vaccine, Pfizer participated in the Subject Expert Committee meeting of the Drug Regulatory Authority of India on February 3. Based on the deliberations at the meeting and our understanding of additional information that the regulator may need, the company has decided to withdraw its application at this time," a company spokesperson said in a statement.

Pfizer will continue to engage with the authority and resubmit its approval request with additional information as it becomes available in the near future, the statement said.

"Pfizer remains committed to making its vaccine available for use by the Government in India and to pursuing the requisite pathway for emergency use authorisation that enables the availability of this vaccine for any future deployment," the spokesperson said.

Pfizer in its application submitted to the drug regulator in December 2020, had sought permission to import the vaccine for sale and distribution in India, besides waiver of clinical trials on Indian population in accordance with the special provisions under the New Drugs and Clinical Trials Rules, 2019, official sources had said.

Updated Date:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

First dose of Pfizer, AstraZeneca shots cut transmission, hospitalisation risk, say UK studies
World

First dose of Pfizer, AstraZeneca shots cut transmission, hospitalisation risk, say UK studies

Being the first nation to begin mass vaccinations in December, over 17 million UK resident have received at least a first dose so far.

Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval
World

Johnson & Johnson's single-dose COVID-19 vaccine safe and effective, says FDA paving way for approval

The vaccine was 66.1% effective in preventing moderate to severe disease and appeared safe, the US Food and Drug Administration said on Wednesday

Pfizer-BioNTech COVID-19 vaccine trial for pregnant women begins in bid to reach important subgroups
World

Pfizer-BioNTech COVID-19 vaccine trial for pregnant women begins in bid to reach important subgroups

AstraZeneca is also monitoring participants in their study who have conceived since their participation in the trial.